AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 795456 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (Inderal)
Number of subjects: 12
Study 30724059 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined sea salt-based oral rinse with Xylitol and lysozyme
Number of subjects: 0
Study 30724059 — intervention group
Group type: COMPARATOR
Intervention: Tooth brushing and flossing alone
Number of subjects: 0
Study 28476814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg i.v. on day 1) plus gemcitabine (1,200 mg/m2 i.v. on days 1‐8)
Number of subjects: 43
Study 28476814 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (7.5 mg/kg i.v.) and cisplatin (60 mg/m2 i.v.) plus gemcitabine (1,000 mg/m2 i.v. on days 1‐8)
Number of subjects: 43
Study 25912693 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal artery denervation (RDN)
Number of subjects: 41
Study 25912693 — intervention group
Group type: COMPARATOR
Intervention: Control (standard pharmacotherapy)
Number of subjects: 41
Study 23949480 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS TEP
Number of subjects: 100
Study 23949480 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic TEP
Number of subjects: 100
Study 21756210 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral lorazepam 2 mg (LOR)
Number of subjects: 28
Study 21756210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 19364310 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/d of oral folic acid
Number of subjects: 60
Study 19364310 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 16362296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel alone
Number of subjects: 16
Study 16362296 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel with 1,200 mg clindamycin
Number of subjects: 16
Study 16362296 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin coadministration
Number of subjects: 16
Study 15596752 — intervention group
Group type: EXPERIMENTAL
Intervention: VRT with attentional cueing (experimental group)
Number of subjects: 19
Study 15596752 — intervention group
Group type: COMPARATOR
Intervention: Standard VRT (control group)
Number of subjects: 19
Study 11158211 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive lowering of blood pressure (BP)
Number of subjects: 0
Study 11158211 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid added to antihypertensive therapy
Number of subjects: 0
Study 11158211 — intervention group
Group type: COMPARATOR
Intervention: Different diastolic BP targets in patients with mild renal insufficiency
Number of subjects: 0
Study 9409789 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic lateral retinacular release (Group I)
Number of subjects: 86
Study 9409789 — intervention group
Group type: EXPERIMENTAL
Intervention: Open lateral retinacular lengthening (Group II)
Number of subjects: 86
Study 8426771 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin therapy
Number of subjects: 69
Study 8426771 — intervention group
Group type: EXPERIMENTAL
Intervention: Local isoniazid therapy (50 mg intranodal instillation)
Number of subjects: 69
Study 3305394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 250 mg b.i.d.
Number of subjects: 125
Study 3305394 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefuroxime axetil 500 mg b.i.d.
Number of subjects: 125
Study 3305394 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 250 mg t.i.d.
Number of subjects: 125
Study 29746878 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-min bouts of stair climbing once every 2 hours for 8 hours
Number of subjects: 9
Study 29746878 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-min bouts of stair climbing once per hour for 8 hours
Number of subjects: 9
Study 29746878 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 9
Study 27738640 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-ALA with SFC (200 mg 5-ALA/229.42 mg SFC per day)
Number of subjects: 53
Study 27738640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 24630878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (500 nM) with 30 mg prasugrel
Number of subjects: 60
Study 24630878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cangrelor (500 nM) with 60 mg prasugrel
Number of subjects: 60
Study 24630878 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (30 mg) without cangrelor
Number of subjects: 60
Study 24630878 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel (60 mg) without cangrelor
Number of subjects: 60
Study 22281608 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant DnaK (rDnaK)
Number of subjects: 0
Study 22281608 — intervention group
Group type: EXPERIMENTAL
Intervention: Live DH5α/pTDK (Sia10-DnaK)
Number of subjects: 0
Study 22281608 — intervention group
Group type: EXPERIMENTAL
Intervention: rDnaK
Number of subjects: 0
Study 22281608 — intervention group
Group type: EXPERIMENTAL
Intervention: DH5α/pTDK
Number of subjects: 0
Study 20329655 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg valsartan (test product)
Number of subjects: 24
Study 20329655 — intervention group
Group type: COMPARATOR
Intervention: 80 mg valsartan (reference product)
Number of subjects: 24
Study 20329655 — intervention group
Group type: EXPERIMENTAL
Intervention: Both products
Number of subjects: 24
Study 18460998 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF, 8 mg.kg body wt)
Number of subjects: 8
Study 18460998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 16401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate/placebo
Number of subjects: 53
Study 16401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin/placebo
Number of subjects: 53
Study 16401310 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin/fenofibrate
Number of subjects: 53
Study 16401310 — intervention group
Group type: COMPARATOR
Intervention: Placebo/placebo
Number of subjects: 53
Study 12847034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation program (face-to-face medication reviews)
Number of subjects: 889
Study 12847034 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacist consultation)
Number of subjects: 889
Study 12847034 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation program
Number of subjects: 889
Study 10478162 — intervention group
Group type: EXPERIMENTAL
Intervention: Confidential prescribing feedback and targeted educational bulletins mailed every 2 months for 6 months.
Number of subjects: 251
Study 10478162 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention until after completion of the study).
Number of subjects: 251
Study 8949324 — intervention group
Group type: EXPERIMENTAL
Intervention: B-score system
Number of subjects: 206
Study 8949324 — intervention group
Group type: COMPARATOR
Intervention: Unaided general practitioners
Number of subjects: 206
Study 8949324 — intervention group
Group type: EXPERIMENTAL
Intervention: B-score prediction
Number of subjects: 206
Study 1820589 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinitapride
Number of subjects: 103
Study 1820589 — intervention group
Group type: COMPARATOR
Intervention: Metoclopramide
Number of subjects: 103
Study 1820589 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 6460947 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoniazid (INH)
Number of subjects: 9
Study 6460947 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 30840197 — intervention group
Group type: EXPERIMENTAL
Intervention: 5000 U/m2 E. coli-derived asparaginase (ASP) IM
Number of subjects: 688
Study 30840197 — intervention group
Group type: COMPARATOR
Intervention: 10000 U/m2 E. coli-derived asparaginase (ASP) IM
Number of subjects: 688
Study 28648540 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicled vein harvesting
Number of subjects: 100
Study 28648540 — intervention group
Group type: COMPARATOR
Intervention: Conventional vein harvesting
Number of subjects: 100
Study 25511781 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 15
Study 25055152 — intervention group
Group type: EXPERIMENTAL
Intervention: Diquafosol 3% and preservative-free sodium hyaluronate 0.1% eye drops
Number of subjects: 150
Study 25055152 — intervention group
Group type: COMPARATOR
Intervention: Diquafosol 3%
Number of subjects: 150
Study 25055152 — intervention group
Group type: COMPARATOR
Intervention: Preserved sodium hyaluronate 0.1%
Number of subjects: 150
Study 22998915 — intervention group
Group type: EXPERIMENTAL
Intervention: Contrast enhanced ultrasound
Number of subjects: 311
Study 22998915 — intervention group
Group type: COMPARATOR
Intervention: Dutasteride pretreatment
Number of subjects: 311
Study 19239354 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate switch in therapy
Number of subjects: 47
Study 19239354 — intervention group
Group type: COMPARATOR
Intervention: Delayed switch (when plasma HIV-1 RNA became > or =10,000 copies/ml)
Number of subjects: 47
Study 17690017 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) targeting pain catastrophizing
Number of subjects: 34
Study 17690017 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 34
Study 15142271 — intervention group
Group type: EXPERIMENTAL
Intervention: Industry-sponsored drug trials
Number of subjects: 45
Study 15142271 — intervention group
Group type: EXPERIMENTAL
Intervention: Design bias in RCTs
Number of subjects: 45
Study 11579889 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate and PSD
Number of subjects: 287
Study 11579889 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated mothers)
Number of subjects: 287
Study 9662762 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin, 500 mg twice daily for 3 days
Number of subjects: 46
Study 9662762 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin, 500 mg four times daily for 7 days
Number of subjects: 46
Study 9662762 — intervention group
Group type: COMPARATOR
Intervention: Cotrimoxazole (trimethoprim 160 mg + sulfamethoxazole 800 mg), twice daily for 7 days
Number of subjects: 46
Study 8161719 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral solution
Number of subjects: 12
Study 8161719 — intervention group
Group type: COMPARATOR
Intervention: Tablets (reference)
Number of subjects: 12
Study 8161719 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection
Number of subjects: 12
Study 3278496 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (0.65 MAC)
Number of subjects: 13
Study 3278496 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.65 MAC)
Number of subjects: 13
Study 2030299 — intervention group
Group type: EXPERIMENTAL
Intervention: Low energy laser treatment (Mid 1500 Irradia laser, wavelength 904 nm, average power output 12 mW, peak value 8.3 W, frequency 70 Hz, pulse train 8000 Hz) applied locally to 6 sites for 30 sec each, total of 10 treatments over 2-3 weeks.
Number of subjects: 49
Study 2030299 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (details not provided)
Number of subjects: 49
Study 1250945 — intervention group
Group type: EXPERIMENTAL
Intervention: Etifoxine 300 mg
Number of subjects: 6
Study 1250945 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐amphetamine 5 mg
Number of subjects: 6
Study 1250945 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31658145 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary tirofiban
Number of subjects: 100
Study 30914350 — intervention group
Group type: EXPERIMENTAL
Intervention: Aqueous extract of saffron capsule (200 mg/day)
Number of subjects: 39
Study 30914350 — intervention group
Group type: COMPARATOR
Intervention: Routine stroke care (control group)
Number of subjects: 39
Study 28073615 — intervention group
Group type: EXPERIMENTAL
Intervention: QPL-Only
Number of subjects: 114
Study 28073615 — intervention group
Group type: EXPERIMENTAL
Intervention: QPL-plus-Coach
Number of subjects: 114
Study 28073615 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 114
Study 25548846 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 units of HBTX‐A
Number of subjects: 488
Study 25548846 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 units of HBTX‐A
Number of subjects: 488
Study 25548846 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 488
Study 23958289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided brachial plexus block using lignocaine with adrenaline and levobupivicaine
Number of subjects: 126
Study 23958289 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic infiltration with lignocaine and levobupivicaine
Number of subjects: 126
Study 23958289 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guided brachial plexus block
Number of subjects: 126
Study 23958289 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetic infiltration
Number of subjects: 126
Study 21420587 — intervention group
Group type: EXPERIMENTAL
Intervention: Apodized multifocal IOL (Group B)
Number of subjects: 106
Study 21420587 — intervention group
Group type: EXPERIMENTAL
Intervention: Full diffractive multifocal IOL (Group C)
Number of subjects: 106
Study 21420587 — intervention group
Group type: COMPARATOR
Intervention: Monofocal IOL (Group A)
Number of subjects: 106
Study 19125045 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinastine 0.05% twice a day plus rewetting drops as required (n = 75)
Number of subjects: 146
Study 17564203 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect, nonspecific, non‐perceptual, conceptual primes
Number of subjects: 0
Study 17564203 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect, conceptual information (category of farm animals)
Number of subjects: 0
Study 17564203 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-linguistic dependent measure
Number of subjects: 0
Study 15848653 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-TAC-MMF (tacrolimus with MMF and daclizumab induction therapy)
Number of subjects: 30
Study 15848653 — intervention group
Group type: COMPARATOR
Intervention: TAC-MMF (tacrolimus with mycophenolate mofetil)
Number of subjects: 30
Study 15848653 — intervention group
Group type: COMPARATOR
Intervention: TAC-MMF
Number of subjects: 30
Study 15848653 — intervention group
Group type: EXPERIMENTAL
Intervention: DAC-TAC-MMF
Number of subjects: 30
Study 11338101 — intervention group
Group type: EXPERIMENTAL
Intervention: Vac-fix immobilization device
Number of subjects: 17
Study 11338101 — intervention group
Group type: COMPARATOR
Intervention: Standard breast board technique
Number of subjects: 17
Study 11338101 — intervention group
Group type: COMPARATOR
Intervention: Patient preference
Number of subjects: 17
Study 9385484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiludronate formulation 9O1 (400 mg/d for 84 +/- 2 days)
Number of subjects: 88
Study 9385484 — intervention group
Group type: COMPARATOR
Intervention: Tiludronate formulation 3C1 (400 mg/d for 84 +/- 2 days)
Number of subjects: 88
Study 8737552 — intervention group
Group type: EXPERIMENTAL
Intervention: Max‐EPA (fish oil rich in polyunsaturated fatty acids)
Number of subjects: 46
Study 8737552 — intervention group
Group type: COMPARATOR
Intervention: CRF patients on conservative treatment (Gp II)
Number of subjects: 46
Study 8737552 — intervention group
Group type: COMPARATOR
Intervention: 3 months post-renal transplant patients (Gp IV)
Number of subjects: 46
Study 3232477 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant infusion of a solution containing glucose (4%), sodium (40 mmol/l), and potassium (20 mmol/l) throughout the observation period
Number of subjects: 0
Study 3232477 — intervention group
Group type: COMPARATOR
Intervention: 5-hour infusion of 10% glucose daily, with potassium and sodium solution in between
Number of subjects: 0
Study 28474437 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP + 0.75% boric acid gel (BA group)
Number of subjects: 39
Study 28474437 — intervention group
Group type: COMPARATOR
Intervention: SRP + placebo gel (placebo group)
Number of subjects: 39
Study 29244851 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevuparin
Number of subjects: 0
Study 26006738 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week exercise programme (exercise-carrousel)
Number of subjects: 0
Study 26006738 — intervention group
Group type: COMPARATOR
Intervention: 2-week social stimulation programme
Number of subjects: 0
Study 23601918 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ankle instability group
Number of subjects: 22
Study 23601918 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group
Number of subjects: 22
Study 22110624 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding (started on the day of admission)
Number of subjects: 56
Study 22110624 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding (started after 60 hours in adults or 36 hours in children)
Number of subjects: 56
Study 22110624 — intervention group
Group type: COMPARATOR
Intervention: Late enteral feeding
Number of subjects: 56
Study 22110624 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral feeding
Number of subjects: 56
Study 22110624 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with aspiration pneumonia
Number of subjects: 56
Study 19363908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel 0.05% (n=674)
Number of subjects: 1537
Study 19363908 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (n=487)
Number of subjects: 1537
Study 19363908 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin gel microsphere 0.1% (n=376)
Number of subjects: 1537
Study 16469022 — intervention group
Group type: EXPERIMENTAL
Intervention: Trospium chloride 20 mg twice daily for 12 weeks
Number of subjects: 658
Study 16469022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 658
Study 12964501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tropisetron 0.05 mg/kg intravenously
Number of subjects: 40
Study 12964501 — intervention group
Group type: COMPARATOR
Intervention: Droperidol 15 micrograms/kg intravenously
Number of subjects: 40
Study 10376458 — intervention group
Group type: EXPERIMENTAL
Intervention: MIST VR training
Number of subjects: 16
Study 10376458 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 8902249 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 6 mg s.c.
Number of subjects: 10
Study 8902249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1828963 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin 50 mg/m2 on days 1, 8, 15, and 22 of radiation therapy
Number of subjects: 246
Study 1828963 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 246
Study 6338416 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (1.7 mg/kg)
Number of subjects: 12
Study 6338416 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbital (1.3 mg/kg)
Number of subjects: 12
Study 6338416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29777228 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 50 mg
Number of subjects: 78
Study 29777228 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 78
Study 26247613 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-affirmation intervention
Number of subjects: 91
Study 26247613 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 91
Study 25675562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture with filiform needle and warm needling therapy combined with positive functional exercise (CZ Dz)
Number of subjects: 192
Study 25675562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints, warm needling and positive functional exercise
Number of subjects: 192
Study 25675562 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture at local acupoints and distal acupoints, acupuncture with filiform needle and warm needling and positive functional exercise
Number of subjects: 192
Study 23615577 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 42
Study 23615577 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (CC)
Number of subjects: 42
Study 20007927 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib
Number of subjects: 119
Study 19014765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate 100 microg twice daily (FP monotherapy)
Number of subjects: 285
Study 19014765 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 5 mg once daily
Number of subjects: 285
Study 19014765 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination fluticasone 100 microg AM and salmeterol twice daily
Number of subjects: 285
Study 19014765 — intervention group
Group type: COMPARATOR
Intervention: Season (spring, fall, or winter vs summer)
Number of subjects: 285
Study 19014765 — intervention group
Group type: COMPARATOR
Intervention: Average seasonal 5% reduction in AM peak expiratory flow
Number of subjects: 285
Study 15836887 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg rimonabant
Number of subjects: 0
Study 15836887 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rimonabant
Number of subjects: 0
Study 15836887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12841342 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerivastatin 0.3 mg at the time of admission (group C+)
Number of subjects: 44
Study 12841342 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (group C−)
Number of subjects: 44
Study 10442494 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine infusion (290 mg/min/1.73 m2 for 1 h) in normal volunteers
Number of subjects: 26
Study 10442494 — intervention group
Group type: COMPARATOR
Intervention: L-arginine infusion
Number of subjects: 26
Study 7587923 — intervention group
Group type: COMPARATOR
Intervention: AO-128 (0.2 mg) with sucrose
Number of subjects: 0
Study 7587923 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-128 (0.03 mg/kg)
Number of subjects: 0
Study 7587923 — intervention group
Group type: EXPERIMENTAL
Intervention: AO-128 (0.1 mg/kg)
Number of subjects: 0
Study 7587923 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0